A Randomized Study of Whether Alfuzosin(Xatral) Helps in the Passage of Kidney Stones
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Patients who present for the first time to Emergency Room with renal colic due to a distal ureteral calculus (as diagnosed with spiral CT scan and KUB) will be randomized to receive Xatral 10mg po once a day or placebo once discharged from the ER. The purpose of this study is to assess if patients treated with Xatral will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
first presentation to ER with renal colic secondary to a distal ureteral stone diagnosed on spiral CT scan
stone radiopaque on KUB, distal to the sacro-iliac joint
patient suitable for discharge from ER
patient willing to return for follow-up on a weekly basis for maximum 4 visits
more than one ureteral calculi
radiolucent stones or cystine stones
prior ipsilateral calculus or ureteral surgery
congenital anomalies of the ureter
patients presents with an absolute indication for intervention
allergy or contraindication to NSAIDs (history of orthostatic hypotension, current systolic BP <90 mmHg)